Trial Profile
MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs MER 3101 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- 06 Nov 2023 Planned End Date changed from 10 May 2024 to 10 Dec 2025.
- 06 Nov 2023 Planned primary completion date changed from 4 May 2024 to 4 Dec 2025.
- 12 Jun 2023 Planned End Date changed from 4 Apr 2023 to 10 May 2024.